by Jason Heaviland | Apr 10, 2026 | Uncategorized
Terms like “comprehensive coverage” and “untargeted detection” are widely used in metabolomics, but they are rarely evaluated in controlled comparisons. Panome Bio conducted a head-to-head study against a widely used legacy platform using identical samples,...
by Jason Heaviland | Mar 31, 2026
Metabolomics Comparison: A Head-to-Head Study Panome Bio conducted a controlled head-to-head metabolomics study using identical samples analyzed by a legacy library-based platform and Next-Generation Metabolomics®️. The results show a nearly 4× increase in detected...
by Jason Heaviland | Mar 31, 2026 | Uncategorized
Researchers run experiments, send samples, and receive results that appear complete. However, a significant portion of the metabolome may never be captured in the final dataset. Not due to sample quality or preparation, but because many metabolomics platforms are...
by Jason Heaviland | Feb 26, 2026
This publication from SynDevRx examines the dual anti-obesity and anti-tumor effects of Evexomostat (SDX-7320), a METAP2 inhibitor evaluated in diet-induced obese mouse and rat models. Using Next-Generation Metabolomics from Panome Bio, the study reveals distinct...
by Jason Heaviland | Feb 26, 2026
Our partners at Indiana University leveraged Next-Generation Metabolomics to profile metabolic and lipidomic changes in gingival crevicular fluid from healthy individuals and patients with periodontitis. Using dual LC-MS platforms and deep-learning–assisted data...
